Wall St futures flat amid US-China trade jitters; bank earnings in focus
Director Jason Aryeh of Ligand Pharmaceuticals INC (NASDAQ:LGND) sold 9,990 shares of common stock on September 23, 2025, for a total value of $1.7 million. The sales occurred in a price range of $170.4051 to $171.9237, near the stock’s 52-week high of $172.45. The transaction comes as LGND shows strong momentum, with a 71% return over the past year. According to InvestingPro data, analysts maintain a bullish outlook with price targets ranging from $164 to $206.
The transactions involved three separate sales. The first sale was for 4,418 shares at a weighted average price of $170.4051, with prices ranging from $169.6625 to $170.6600. The second sale involved 4,628 shares at a weighted average price of $170.9643, with prices ranging from $170.6850 to $171.6050. The final sale was for 954 shares at a weighted average price of $171.9237, with prices ranging from $171.7250 to $172.2400. The company, currently valued at $3.32 billion, maintains strong financial health with a current ratio of 5.45, indicating solid liquidity.
Following these transactions, Aryeh directly owns 69,289 shares of Ligand Pharmaceuticals INC. Additionally, he indirectly owns 51,594 shares through certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates, and 5,025 shares by Trust. For comprehensive insider trading analysis and 12 additional key insights about LGND, visit InvestingPro.
In other recent news, Ligand Pharmaceuticals has been active with significant financial maneuvers and analyst attention. The company completed a $460 million convertible notes offering, raising approximately $445.1 million after fees and expenses. This follows a prior announcement of pricing $400 million in convertible senior notes, with an option for purchasers to buy an additional $60 million. The capital raise has influenced analyst firms to adjust their outlooks on Ligand. Oppenheimer increased its price target to $190, citing the recent capital raise and maintaining an Outperform rating. Benchmark also raised its price target to $175, highlighting Ligand’s strong second-quarter earnings report. H.C. Wainwright went further, setting a new target of $206, following the FDA’s approval of updated labeling for FILSPARI, which includes reduced monitoring requirements. These developments reflect a period of strategic financial activity and positive analyst sentiment for Ligand Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.